Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Vanda Pharmaceuticals Inc. | vnda12312020ex321.htm |
| 10-K - 10-K - Vanda Pharmaceuticals Inc. | vnda-20201231.htm |
| EX-31.2 - EX-31.2 - Vanda Pharmaceuticals Inc. | vnda12312020ex312.htm |
| EX-31.1 - EX-31.1 - Vanda Pharmaceuticals Inc. | vnda12312020ex311.htm |
| EX-21.1 - EX-21.1 - Vanda Pharmaceuticals Inc. | vnda12312020ex211.htm |
| EX-10.41 - EX-10.41 - Vanda Pharmaceuticals Inc. | vndaex104112312020.htm |
| EX-10.40 - EX-10.40 - Vanda Pharmaceuticals Inc. | vndaex104012312020.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-133368, No. 333-138070, No. 333-141571, No. 333-148924, No. 333-156995, No. 333-164567, No. 333-171962, No. 333-179265, No. 333-186509, No. 333-193614, No. 333-201754, No. 333-209144, No. 333-212255, No. 333-218774, No. 333-225599 and No. 333-239103) of Vanda Pharmaceuticals Inc. of our report dated February 11, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Baltimore, Maryland
February 11, 2021